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cen years ago, when the increased prevalence of heart
ailure along with the recognition of the limitations of
xisting therapies have forced the consideration of new
herapeutic options, implantation of contractile cells into
carred myocardium has emerged as an attractive strategy.
his approach was actually backed by the long-standing
uccessful outcomes of bone marrow and skin transplanta-
ion that first rationalized the use of cells as therapeutic
gents. Although it was recognized that the most logical
pproach would have been to use cardiac cells, this turned
ut not to be possible: fetal cardiomyocytes raised compli-
ated ethical, logistical, and technical issues (1); there was
and still there is) no means for effectively mobilizing a
ypothetical pool of resident stem cells (2); and research on
mbryonic stem cell-derived cardiac progenitors was still in
nfancy. Investigators then looked at cells that might act as
See page 1869
ardiomyocyte surrogates, and, in this setting, autologous
keletal myoblasts were found clinically attractive because of
he easiness of procurement, their in vitro scalability, and
he lack of serious concerns about tumoriginicity. A large
ody of experimental evidence was then generated that
howed, in a robust and consistent fashion, that skeletal
yoblasts implanted in post-infarcted myocardium differ-
ntiated into myotubes and improved left ventricular func-
ion. Although the precise mechanism of action was still
lusive, these experimental data paved the way for the
arly-phase clinical studies, which were then followed by a
rst wave of randomized controlled trials. Now that the
esults of these trials are available, one has to admit that,
nce again in medicine, clinical outcomes have not matched
he hopes raised by the animal data. In the MAGIC
Myoblast Autologous Grafting in Ischemic Cardiomyopa-
hy) trial (3), which randomized 97 patients, the primary
nd points (an improvement in global and regional left
entricular function) were not achieved despite a significant
eversal of remodeling in patients receiving the highest dose
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aculté de Médecine; and the INSERM U 633, Paris, France.f myoblasts, compared with that of the placebo-injected
roup. More recently, a catheter-based study, which has
ntailed the endoventricular delivery of myoblasts, has also
ailed to show substantial benefits in the treated cohort (P.
erruys, personal communication, March 2008).
Several factors could have accounted for these disappoint-
ng results, including a low rate of initial cell retention, a
igh rate of subsequent cell death, and the inability of
ngrafted myoblasts to establish functional electro-
echanical connections with the host cardiomyocytes (4).
owever, there is another factor of failure that has been so
ar poorly investigated: the use of the bulk of unfractionated
yoblasts, as opposed to a specific subpopulation of these
yogenic cells that might feature a greater cardiac repair
otential. The major interest of the paper by Okada et al. (5)
ublished in this issue of the Journal is to have identified,
haracterized, and functionally assessed such a population.
ndeed, in 2005, Winitsky et al. (6) described, in the mouse
uscle, a pool of cells that they named skeletal precursors of
ardiomyocytes because of their purported ability to differ-
ntiate into cardiomyocytes. That same year, Oshima et al.
7) described a population of murine muscle-derived stem
ells, which, despite the expression of surface markers
ifferent from those of skeletal precursors of cardiomyo-
ytes, were also reported to acquire a cardiac phenotype,
artly by fusion with host cardiomyocytes. Of note, in a rat
odel of myocardial infarction, these cells featured a greater
nd more sustained engraftment, induced more angiogene-
is, and effected greater improvements in left ventricular
unction than unsorted myoblasts (7). The same group
ubsequently extended this research by describing, in the
uman muscle, a population of myoendothelial cells (8)
efined by a positive staining for the CD56, CD34, and
D144 markers and which was shown to share several
imilarities with mouse muscle-derived stem cells, including
multidifferentiation potential and an increased resistance
o oxidative stress. The latter characteristic was postulated to
ccount for the greater muscle regeneration capacity of these
yoendothelial cells compared with myoblasts after transplan-
ation in injured skeletal muscle of severe combined immuno-
eficiency mice (8).
The study by Okada et al. (5) extends these data and
trengthens their potential therapeutic interest by showing
hat this population of myoendothelial cells also displays a
ardiac repair capacity. The authors used a mouse model of
cute infarction and a comprehensive combinatorial ap-
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Skeletal Myoblasts for Cardiac Repair December 2, 2008:1881–3roach, which allowed them to demonstrates that after 6
eeks the myoendothelial cells provide a better recovery
han unsorted myoblasts or sorted populations of either
yogenic (CD56CD34CD144) or endothelial cells
CD56CD34CD144). This conclusion was based on a
reater preservation of left ventricular systolic function (but
ithout limitation of remodeling), less scar formation, in-
reased cell engraftment, angiogenesis, and endogenous cardi-
myocyte proliferation and decreased early post-infarct apo-
tosis compared with cells defined by a merely myogenic or
ndothelial phenotype. These benefits are significant, but those
ertaining to function should be interpreted cautiously in that
aseline measurements were apparently not performed so that
vidence for a strict comparability of initial infarct sizes is
acking; under these conditions, the interpretation of between-
roup post-transplantation outcomes is clearly less straightfor-
ard. Overall, however, the protective effects of the myoendo-
helial cells look convincing and seem to be primarily related to
aracrine effects mediated, in part, by vascular endothelial
rowth factor whose secretion was expectedly shown to be
p-regulated under hypoxic conditions.
Because the clinical results of the early-phase cell therapy
rials have not matched the initially high level of expecta-
ions (this is not specific for myoblasts in heart failure but
lso extends to bone marrow cells in acute myocardial
nfarction), a part of the medical community is now wrongly
nclined to step back from this mode of therapy. The fact is
hat the field is still at an early stage and that we are
truggling to find the right cells and the right mode of
elivering them in the right patient population. To some
xtent, the situation is not so different from that of the first
eart transplantations, which were associated with a dis-
ressingly dismal prognosis. If basic scientists and clinicians
ad then stopped being committed to pursue this approach,
ne would never have found the immunosuppressive drugs
hat have strikingly improved transplantation outcomes.
imilarly, we now have to use the existing database on
ardiac cell therapy as a building block to move the field
orward. The carefully designed and executed study by
kada et al. (5) could contribute to this endeavor by raising
he possibility that skeletal myoblast transplantation might
e optimized by extracting from the heterogeneous pool of
yogenic cells a discrete fraction that combines a dual
otential for myogenesis and angiogenesis and can thus
ontribute to its self-survival. However, the clinical rele-
ance of these findings requires that at least 3 main issues be
ddressed.
The first is related to scale-up. This is particularly critical
f one takes into account that this myoendothelial cell
opulation only represented a tiny fraction of the whole
uscular biopsy (1.8%). This number might be even smaller
f cells were harvested from older donors (a likely situation
n cardiac cell therapy), and, furthermore, it likely decreases
uring cell processing because of the phenotypic changes
ccurring over the course of expansion. From this stand-
oint, it is noteworthy that these cells are reported to have petained their endothelial phenotype, which contrasts with
he common observation that the CD34 antigen usually
isappears after several passages. Furthermore, in the cur-
ent study, Okada et al. (5) injected cells in the acutely
nfarcted mouse heart. The time required for growing these
ells (a few weeks) is clearly not compatible with an
mergency setting, and, in clinical practice, these cells look
etter suited for a more chronic use in patients with heart
ailure. In this case, the cardiomyocyte deficit has been
stimated in the range of 1 billion (9), and it is thus critical
o validate, in a large animal model more closely mimicking
he human situation, that this CD34CD56CD144
opulation can be expanded up to the high target cell
umbers required for adequate cardiac repair. It is equally
mportant to ensure that the local signals that may help
rive their fate in situ, and which were apparently present in
he acutely injured myocardium, will still be operative once
carring has occurred.
The second issue is related to the functional integration
f the cellular graft. The data reported in this study clearly
ndicate that these myoendothelial cells fail to differentiate
nto cardiomyocytes. While this does not preclude cardio-
rotective effects mediated by the paracrine activation of
ost-associated cytoprotective pathways, these effects might
ot be sufficient to translate into clinically meaningful
mprovements in patient outcomes, which likely requires the
rovision of new donor-derived cardiomyocytes for replac-
ng the dead ones. From this standpoint, it is noteworthy
hat 8 skeletal muscle-resident stem cell populations have
ow been described (10). These populations differ by several
spects (origin, method of isolation, growth conditions,
ifferentiation potential), but, importantly, only 2 of them
both of murine origin) have been shown to display a cardiac
ifferentiation potential, which was actually demonstrated
n vivo in only 1 case (6). It is, therefore, likely that
egardless of their paracrinally mediated cardioprotective
ffects, the human skeletal muscle-derived cells cannot
chieve the ultimate objective of creating new myocardium,
hich should stimulate research aimed at identifying alter-
ate sources of clinically usable cardiac progenitors (11).
The third issue is related to the potential arrhythmogenic
otential of these myoendothelial cells. In the MAGIC trial
here all patients were instrumented with an internal
ardioverter-defibrillator, there was no significant differ-
nce, at the 6-month study point, in the number of
rrhythmic events between myoblast-treated patients and
hose injected with a placebo solution (3). However, a
reater propensity for arrhythmias during the early post-
perative period cannot still be completely eliminated and is
sually attributed to the electrical insulation of the cell
lusters that may create conduction blocks setting the stage
or re-entries (12). This, in turn, is thought to reflect the
ailure of myoblasts to express connexin-43. As the
D34CD56CD144 population described by Okada
t al. (5) does not express this gap junction protein, its
otential proarrhythmic risk cannot be eliminated and
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arge animal models.
It is still too early to know whether the myoendothelial
ell population described in this study will ever come to
linical practice. The merit of this paper, however, is to
ighlight that our use of stem cells has, so far, been rather
rude and that refining cell identification and sorting could
e a fruitful approach for upgrading the clinical outcomes of
ell transplantation.
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